Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0271678X15606714 http://scihub22266oqcxt.onion/10.1177/0271678X15606714 C4776311!4776311 !26661169     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26661169 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Cereb+Blood+Flow+Metab 2016 ; 36 (3 ): 596-605 Nephropedia Template TP {{tp|p=26661169 |t=2016. A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke |pdf=|usr=}}{{26661169 }} gab.com Text A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke JO: J Cereb Blood Flow Metab http://www.kidney.de/pget.php?&tw=1&pmid=26661169 #FOAvip Stroke represents a global challenge and is a leading cause of permanent disability worldwide. Despite much effort, translation of research findings to clinical benefit has not yet been successful. Failure of neuroprotection trials is considered, in part, due to the low quality of preclinical studies, low level of reproducibility across different laboratories and that stroke co-morbidities have not been fully considered in experimental models. More rigorous testing of new drug candidates in different experimental models of stroke and initiation of preclinical cross-laboratory studies have been suggested as ways to improve translation. However, to our knowledge, no drugs currently in clinical stroke trials have been investigated in preclinical cross-laboratory studies. The cytokine interleukin 1 is a key mediator of neuronal injury, and the naturally occurring interleukin 1 receptor antagonist has been reported as beneficial in experimental studies of stroke. In the present paper, we report on a preclinical cross-laboratory stroke trial designed to investigate the efficacy of interleukin 1 receptor antagonist in different research laboratories across Europe. Our results strongly support the therapeutic potential of interleukin 1 receptor antagonist in experimental stroke and provide further evidence that interleukin 1 receptor antagonist should be evaluated in more extensive clinical stroke trials. Twit Text FOAVip A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke ????J Cereb Blood Flow Metab http://www.kidney.de/pget.php?&tw=1&pmid=26661169 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26661169 #FOAvip English Wikipedia <ref>{{Cite pmid|26661169 }}</ref> A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke #MMPMID26661169 Maysami S ; Wong R ; Pradillo JM ; Denes A ; Dhungana H ; Malm T ; Koistinaho J ; Orset C ; Rahman M ; Rubio M ; Schwaninger M ; Vivien D ; Bath PM ; Rothwell NJ ; Allan SM J Cereb Blood Flow Metab 2016[Mar]; 36 (3 ): 596-605 PMID26661169 show ga Stroke represents a global challenge and is a leading cause of permanent disability worldwide. Despite much effort, translation of research findings to clinical benefit has not yet been successful. Failure of neuroprotection trials is considered, in part, due to the low quality of preclinical studies, low level of reproducibility across different laboratories and that stroke co-morbidities have not been fully considered in experimental models. More rigorous testing of new drug candidates in different experimental models of stroke and initiation of preclinical cross-laboratory studies have been suggested as ways to improve translation. However, to our knowledge, no drugs currently in clinical stroke trials have been investigated in preclinical cross-laboratory studies. The cytokine interleukin 1 is a key mediator of neuronal injury, and the naturally occurring interleukin 1 receptor antagonist has been reported as beneficial in experimental studies of stroke. In the present paper, we report on a preclinical cross-laboratory stroke trial designed to investigate the efficacy of interleukin 1 receptor antagonist in different research laboratories across Europe. Our results strongly support the therapeutic potential of interleukin 1 receptor antagonist in experimental stroke and provide further evidence that interleukin 1 receptor antagonist should be evaluated in more extensive clinical stroke trials. |Animals [MESH] |Brain Edema/complications/drug therapy/immunology/pathology [MESH] |Brain Ischemia/complications/drug therapy/immunology/pathology [MESH] |Brain/drug effects/immunology/pathology [MESH] |Disease Models, Animal [MESH] |Drug Evaluation, Preclinical [MESH] |Inflammation/complications/drug therapy/immunology/pathology [MESH] |Interleukin 1 Receptor Antagonist Protein/*therapeutic use [MESH] |Male [MESH] |Mice, Inbred BALB C [MESH] |Mice, Inbred C57BL [MESH] |Neuroprotective Agents/*therapeutic use [MESH] |Receptors, Interleukin-1/*antagonists & inhibitors/immunology [MESH]A cross-laboratory preclinical study on the effectiveness of interleuk(epmc).pdf DeepDyve Pubget Overpricing